公司資料
TransMedics 股價、新聞與催化劑
- 股票代碼:
- TMDX
- 交易所:
- NASDAQ
- 產業:
- MedTech
- 所在地:
- United States
股票表現
78.64 USD (-5.76%)
收盤價
最後更新: 2026年10月1日
2.37B USD
市值
股價為何變動
截至 2026年10月1日，TMDX 下跌 5.76%，收於 $78.64。目前新聞監測窗口內未發現新的同公司新聞。
公司概覽
Organ Transplant Technology Company
TransMedics develops technology and services intended to expand access to donor organs for patients with end-stage heart, lung, and liver failure.
Organ Care System
The Organ Care System uses portable extracorporeal warm perfusion to preserve donor organs in a functioning state outside the body. The platform also allows clinicians to assess organ condition before transplantation.
Heart, Lung, and Liver Applications
Separate OCS configurations support donor hearts, lungs, and livers. The technology is designed to reduce the limitations of static cold storage and enable the use of organs that might otherwise be declined.
National OCS Program
The National OCS Program provides a coordinated service that includes trained clinical specialists, logistics, and OCS deployment. This turnkey model helps transplant centers access the technology without building every operational capability internally.
Integrated Aviation and Development Pipeline
TransMedics is building dedicated aviation and logistics capacity in the United States and Europe to transport organs and clinical teams. Development investments include OCS Kidney, next-generation OCS technology, and clinical programs intended to expand the platform.
未來催化劑
近期新聞
新聞標題由機器翻譯，詳情為英文原文。
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。